Cisplatin has dramatically improved the survival rate of cancer patients, but it has also
increased the prevalence of hearing and neurological deficits in this population. Cisplatin …

Since the introduction of platinum-based combination chemotherapy, particularly cisplatin,
the outcome of the treatment of many solid tumours has changed. The leading platinum …

Neurotoxic side effects of chemotherapy occur frequently and are often a reason to limit the
dose of chemotherapy. Since bone marrow toxicity, as the major limiting factor in most …

Although it is well known that cisplatin causes a sensory neuropathy, the primary site of
involvement is not established. The clinical symptoms localized in a stocking-glove …

Forty‐five patients with cisplatin‐induced peripheral neuropathy (PN) were evaluated
retrospectively after treatment with cumulative doses of cisplatin ranging from 201 to 1952 …

Combination chemotherapy will, in many patients, provoke neurological symptoms or signs
during or after treatment. These side-effects have become more apparent as more patients …

The authors prospectively evaluated the effects of three different schedules of cisplatin
(DDP) administration in 60 patients with advanced epithelial ovarian cancer. The individual …

Sixteen patients treated with cisplatin (CDDP) 40 mg/m 2 on days 1–5 every 4 weeks for
three courses (cumulative dose 600 mg/m 2) were clinically and neurophysiologically tested …

Cisplatin (Platinol@) is an antineoplasic agent currently indicated for the management of
metastatic testicular and ovarian carcinoma and for advanced bladder cancer. It is also …

A prospective study was performed in patients treated with cisplatin to evaluate the
occurrence and degree of central, peripheral and autonomic neuropathy and to determine …